An 8-amino acid peptide encoding a sequence of the transmembrane region of the T cell receptor ␣ chain (TCR-␣) was shown to inhibit T cell function by preventing functional assembly of the T cell receptor (mimic peptide). To avoid systemic immunosuppression by peptide application in vivo, we used a topical application of the peptide. In the system of murine contact sensitivity, topical application of the peptide inhibited the elicitation of contact sensitivity following application of a contact allergen in sensitized animals. Alternatively, when naked DNA encoding the peptide sequence was injected into skin before application of a contact allergen to Keywords: TCR; T cell function; allergical contact dermatitis; T cell mediated disease; DNA vaccination
The ␣, ␤ T cell receptor (TCR) is a multisubunit transmembrane complex composed of at least six different polypeptides (␣, ␤, ␥, ␦, ⑀ and ). 1 The TCR-␣ and -␤ subunits appear as a disulfide-linked homodimer that is the ligand binding site and determines the specificity of the receptor. For signal transduction into the cytoplasm, the TCR is noncovalently associated with the CD3 molecules (CD3-␥, -␦, -⑀ and -). The transmembrane region of the TCR is of critical importance for a functional assembly of the T cell receptor. 2 The transmembrane region of the TCR-␣ chain is highly conserved in different species. Studies on the assembly of the multisubunit TCR demonstrated that the stable interactions between the TCR-␣ chain and the CD3 molecule were located to eight amino acids within the transmembrane region of TCR-␣. [3] [4] [5] Manolios et al 6 demonstrated that an eight amino acid peptide mimicking the TCR-␣ chain inhibits T cell function in vitro and in vivo. These investigators showed the inhibitory effect of this peptide in different murine autoimmune disease models. The disadvantage of the systemic application of the mimic peptide is the general and long-lasting immunosuppressive effect that is unwanted for human applications.
Allergic contact dermatitis (ACD) is an example for a T cell mediated delayed-type hypersensitivity (DTH) reaction. 7 sensitized animals, local immunosuppression was also observed. To investigate the effects of this peptide in humans, patients with psoriasis, atopic eczema, lichen planus, or contact dermatitis were treated topically with mimic peptide or control peptide. All patients except for one reported a marked improvement or cure of their skin disease following application of the TCR-␣ peptide, but not controls. These data indicate that TCR-␣ peptide or cDNA treatment might be a proper treatment for human T cell-mediated dermatoses substituting for corticosteroids. Gene Therapy (2000) 7, 1000-1004.
other DC take up hapten, migrate to regional lymph nodes and activate naive T cells. In the elicitation phase, sensitized T cells are already present in skin. After a second application of the contact allergen, these cells proliferate following local antigen presentation and produce an inflammatory infiltrate by recruiting other leukocytes. 8 Blocking T cell functions early in the elicitation phase should therefore abrogate ACD reactions.
The goal of our study is to demonstrate that a mimic peptide against the transmembrane region of the TCR can function as a local immunosuppressive agent in T cellmediated inflammatory skin reactions such as contact sensitivity or atopic dermatitis in mouse and man.
For our study we utilized a synthetic peptide (= mimic peptide or core peptide; Gly-Leu-Arg-Ile-Leu-Leu-LeuLys-Val) containing a sequence of the T cell receptor-␣ (TCR-␣) chain and a control peptide (Leu-Gly-Ile-LeuLeu-Leu-Gly-Val) where two amino acid residues have been exchanged. For better transmembrane passage the peptides were conjugated with palmitic acid. To assess functional activity of the mimic peptide in vitro we used an allogeneic mixed leukocyte reaction (MLR) with human dendritic cells (DC) as antigen presenting cells (APC). Preincubation of CD4 + or CD8 + T cells with 100 m to 500 m of the mimic peptide for 1 h significantly reduced proliferation of T cells in contrast to the control peptide ( Figure 1 ). Addition of anti-CD3 mAb to mimic peptide-preincubated T cells completely restored proliferation. In the presence of anti-CD3, mimic peptide treated T cells showed the same rate of proliferation as untreated T cells (data not shown). Thus peptide treatment only inhibits T cell function, but is not toxic. To assess functional activity of the mimic peptide in vivo, mice were sensitized with an experimental contact allergen (TNCB) and challenged 5 days later. Before challenge, either mimic peptide at a concentration of 1 mg or control peptide were applied epicutaneously. Animals treated with mimic peptide showed a significantly reduced ear swelling response of about 50% as compared with the control group. This result shows that the mimic peptide inhibits the elicitation phase of contact sensitivity ( Figure 2 ). Suppression was not complete as mice constantly scratched their ears and therefore wiped TCR peptides off their skin. If contralateral ears were painted with allergens, but not treated with mimic peptide, swelling reactions were unaffected pointing to a local effect of the peptide. Also mimic peptide did not have any effect on non-T cell-mediated edematous swelling reactions as application to already inflamed ear tissue (eg 24 h after application of the contact allergen to the ears of sensitized animals) did not result in a reduction of the swelling response (data not shown). Also, there was no effect of the mimic peptide on the induction phase of ACD.
To exclude a systemic effect of the peptide on T cell function in peptide-treated animals, allogeneic MLR assays were performed with T cells derived from either hapten-treated or untreated, mimic peptide-exposed or unexposed animals ( Figure 3 ). As shown, treatment with mimic peptide did not inhibit T cell proliferation in any of the groups tested. These results demonstrate that treatment with mimic peptide inhibits only the elicitation phase of murine contact sensitivity and has no general immunosuppressive effect.
To achieve a more stable and prolonged effect of the peptide in vivo, we used naked cDNA encoding a sequence of the TCR-␣ chain (pTCRTMB) or control DNA (pTCRTMBA). Prior studies had shown that skin, when injected with naked DNA, expressed the injected gene and produced a biologically active protein. 9 In contrast to humans where the injected genes are expressed mostly in the epidermis, mouse skin expressed the plasmid DNA at multiple sites including epidermis, dermis, adipocytes and muscle fascicles. 10, 11 To assay for functional activity of the DNA in vitro 2 x 10 5 human HaCaT cells (epidermal keratinocytes) were transfected with 3 g pTCRTMB plasmid or the control DNA (pTCRTMBA) by lipofection. Supernatants were collected, 24 h after transfection, and CD4
+ or CD8 + T cells were preincubated with these supernatants for 2 h. Proliferation of these T cells was determined in an allogeneic MLR using DC as APC. Proliferation of both CD4 + or CD8
+ T cells was reduced by preincubation with supernatant of pTCRTMB transfected cells, but not by the negative control plasmid (pTCRTMBA) by 70% ( Figure  4) . Incubation with an anti-CD3 mAb abolished this inhibitory effect (Figure 4) .
Studies of the efficiency of immunization with naked

Figure 4 Inhibitory effects of pTCRTMB on alloantigen-induced proliferation of CD4 + or CD8 + T cells. The plasmid pTCRTMB was constructed by cloning a 27 bp large sequence (5Ј-GGGTTCCGAATCCTCCTCCT GAAAGTG-3Ј) containing a part of the T cell receptor transmembrane region into a EcoRV site of the pSecTag2a vector (Invitrogen, San Diego, CA, USA). The negative control plasmid pTCRTMBA contains the same fragment in antisense orientation in the expression vector pSecTag2a. The pSecTag2A contains a secretory Ig leader sequence. T cells were preincubated with supernatants from transfected HaCaT-cells for 2 h. T cells left untreated or preincubated with pTCRTMBA served as controls. T cell proliferation was restored in mimic peptide-treated cells by addition of 20 ng/ml anti-CD3 mAb (pTCRTMB + anti-CD3). T cell proliferation was measured by 3 H-TdR uptake after 4 days. Results were expressed as the mean ± standard error (s.e.m.). The human keratinocyte cell line HaCat were cultured in DMEM medium supplemented with 10% FCS and 2 mm glutamine.
DNA showed that ear pinna is the most effective vaccination site compared with skeletal muscle or dermis of abdominal skin. 12 To assess functional activity of the DNA in vivo we sensitized mice with 1% TNCB. Three days later 50 g of pTCRTMB or the control DNA or PBS alone were injected into the ear skin. Plasmid peptide expression was visualized by antibody staining 24 h later and expression was detectable in epidermal and dermal compartments (not shown). A challenge dose of TNCB was applied to the ears 24 h after injection of plasmid into ear skin, and 24 h thereafter ear swelling responses were determined. The pTCRTMB-plasmid treated group (group B) showed a significantly reduced ear swelling response of about 60% as compared with the control group A or C ( Figure 5 ). Suppression of ear swelling response was not complete as not the whole pinna of the ear that was, however, exposed to the allergen, could be injected. Further controls indicated that pTCRTMB does not have any effect on nonspecific irritation, eg by acetone. These results show that the injection of naked pTCRTMB DNA can inhibit the elicitation phase of contact sensitivity.
To investigate the effects of the peptide on human skin diseases further, various patients suffering from T cellmediated skin diseases were treated with the purified peptide. 13 Five normal individuals were sensitized with 2% DCP (a nontoxic contact allergen used for the therapy of alopecia areata). One week later they were painted with a hydrophobic cream containing 1 mg/g of the purified TCR peptide or control peptide. Immediately afterwards, a challenge dose of 0.1% DCP was applied epicutaneously to the same skin site. The inflammatory skin reactions were documented by histology and photography 24 h later ( Figure 6 ). TCR peptide-treated skin showed virtually no signs of inflammation. In contrast, control peptide-treated skin showed marked contact eczema and T cell infiltration with spongiosis and blisters. Mimic peptide-mediated inhibition of contact sensitivity reactions was comparable to the effects of topical betamethasone, a potent glucocorticoid used in the treatment of contact allergy.
We also tested the effects of the peptide on patients with psoriasis (2), atopic dermatitis (5), and lichen planus (2) . All of these diseases are characterized by a strong T cell infiltrate especially at the disease onset and all of them are responsive to corticosteroid treatment. Following informed consent all patients were treated with the cream containing 1 mg of mimic peptide or control peptide on an area of approximately 1 cm 2 on 3 consecutive
Gene Therapy days ( Table 1 ). All patients except for one reported a marked improvement or cure of the disease following application of the TCR-␣ peptide, but not controls. When compared with betamethasone application, mimic peptide inhibited inflammatory reactions equally strong in the same patient. These data indicate that TCR-␣ peptide treatment might be a proper treatment for human T cellmediated dermatoses substituting for corticosteroids.
Our study indicates that a peptide generated from the transmembrane region of the T cell receptor-␣ chain inhibits T cell function. We show that mimic peptides suppress T cell functions for CD4
+ and CD8 + T-lymphocytes in vitro. We also demonstrate that addition of stimulatory anti-CD3 mAb to DC/T cell cultures overcomes this inhibitory effect. Thus peptide treatment is not a toxic effect, but only prevents T cell signaling. In contrast to the studies by Manolios et al, 6 who demonstrated the immunosuppressive effect of the peptide in three T cellmediated diseases by systemic application resulting in long-lasting general immunosuppression, we show a local immunosuppressive effect in skin by topical application. Topical application of the peptide results in suppression of model T cell diseases, such as ACD in mice. Injection of naked DNA encoding for the peptide, but not controls, results in inhibition of the elicitation phase of ACD and suppression of the inflammatory infiltrate. In man, TCR peptides are capable of suppressing and preventing T cell-mediated dermatoses such as ACD, lichen planus, or atopic dermatosis even more potently than in mice. This result might seem surprising at first glance as our murine study did not show any effect of the mimic peptide on swelling reactions in mice 24 h after hapten treatment. It should be noted, however, that in man the effect of the mimic peptide was strongest when applied to freshly arising skin lesions. The effect was much less pronounced when already existing lesions were treated where cells other than T-lymphocytes are present. This points to a specific inhibition of T cell function of our mimic peptide.
Our results provide first evidence that topical application of a peptide corresponding to the transmembranous region of the TCR exerts a local immunosuppressive effect by deactivating T cell function in skin. The effect of TCR peptides is therefore comparable to the topical 
L-P X Patients with P = psoriasis (2), AD = atopic dermatitis (5) and L-P = lichen planus (2) were treated with the antisense peptide following informed consent. For this, 1 mg of mimic peptide/g cream or control peptide were applied to approximately 1 cm 2 of diseased skin for 3 consecutive days. Results were shown after 3 days of treatment.
application of corticosteroids. As steroids, especially when applied chronically, show a long list of unwanted side-effects such as skin atrophy or fragile blood vessels, topical application of TCR mimic peptide might be a promising alternative therapy for T cell-mediated dermatoses. It will be the goal of future studies to clarify the potency and safety of this approach.
